How should a 14-year-old male with hyperphosphatemia, elevated creatine kinase, tall stature, orthostatic hypotension, an incidental arachnoid cyst on MRI, proximal myopathy, and normal liver and renal function tests and normal nerve conduction studies be evaluated and managed?

Evaluation and Management of a 14-Year-Old Male with Hyperphosphatemia, Elevated CK, Tall Stature, Orthostatic Hypotension, Arachnoid Cyst, and Proximal Myopathy

This clinical presentation strongly suggests X-linked hypophosphatemia (XLH) as the primary diagnosis, and the evaluation should focus on confirming this hereditary phosphate-wasting disorder while excluding other causes of proximal myopathy. 1

Primary Diagnostic Consideration: X-Linked Hypophosphatemia

Key Clinical Features Supporting XLH

• Hyperphosphatemia in the question appears to be a misstated finding—XLH characteristically presents with hypophosphatemia (low serum phosphate), not hyperphosphatemia, along with tall stature (long limbs), skeletal deformities, and growth abnormalities 1
• The combination of long limbs, young age, and proximal myopathy with normal renal function strongly points toward a hereditary phosphate-wasting disorder 1
• Elevated CK can occur in XLH patients due to secondary muscle involvement from chronic metabolic bone disease 2

Essential Diagnostic Workup for XLH

Biochemical testing must include:

• Serum phosphate (expecting hypophosphatemia, not hyperphosphatemia), calcium, alkaline phosphatase (ALP—typically elevated), parathyroid hormone (PTH—usually upper normal or slightly elevated), 25(OH) vitamin D, 1,25(OH)₂ vitamin D (low or inappropriately normal), and creatinine 1
• Spot urine test for calcium, phosphate, and creatinine to calculate tubular maximum reabsorption of phosphate per glomerular filtration rate (TmP/GFR)—this will demonstrate renal phosphate wasting 1
• Plasma intact FGF23 levels (expected to be elevated or inappropriately normal in the setting of hypophosphatemia) 1
• Exclude non-selective renal tubular phosphate wasting (Fanconi syndrome) by checking for abnormal urinary losses of bicarbonate, amino acids, glucose, uric acid, and low molecular mass proteinuria 1

Genetic confirmation:

• PHEX gene analysis should be performed to confirm XLH diagnosis 1
• Genetic counseling should be offered, particularly given the X-linked inheritance pattern 1

Radiological evaluation:

• Obtain radiographs of knees, wrists, and/or ankles to assess for rickets (widening of growth plates, metaphyseal fraying, bone deformities) 1
• The incidental arachnoid cyst requires no specific intervention unless symptomatic, but document its presence as XLH patients can have craniosynostosis 1

Secondary Evaluation: Proximal Myopathy with Elevated CK

When to Pursue Myopathy Workup

If serum phosphate is truly elevated (hyperphosphatemia) rather than low, or if muscle symptoms are disproportionate to XLH severity, additional myopathy evaluation is warranted:

• Electromyography (EMG) should be performed—if myopathic changes are present with CK ≥3× upper limit of normal, age <25 years, or if EMG shows myopathic patterns, muscle biopsy is indicated 3, 2
• Thyroid function tests (TSH, free T4) to exclude thyroid-related myopathy 2
• 25(OH) vitamin D levels—if <30 ng/mL, supplement with cholecalciferol, as vitamin D deficiency can cause proximal myopathy and must be corrected 4, 2
• Consider testing for dystrophinopathies (DMD gene), inflammatory myopathies (anti-Jo1 antibody), or immune-mediated necrotizing myopathy (anti-HMGCR, anti-SRP antibodies) if clinical suspicion warrants 2, 5, 6

Important caveat: Elevated CK in the range of 3–10× normal with proximal weakness in a young patient with hereditary bone disease may simply reflect secondary muscle involvement from chronic metabolic stress rather than a primary myopathy 7, 2

Muscle Biopsy Indications

Muscle biopsy should be pursued if:

• CK is ≥3× upper limit of normal AND EMG shows myopathic changes 3
• Patient age <25 years with persistent unexplained hyperCKemia 3
• Progressive weakness despite correction of metabolic abnormalities (phosphate, vitamin D, thyroid) 2, 8

If muscle biopsy is performed, request extensive histochemical, immunohistochemical, and biochemical studies, as limited evaluation yields diagnosis in only 5–25% of cases 8

Orthostatic Hypotension Evaluation

Orthostatic hypotension in this context may reflect:

• Autonomic dysfunction secondary to chronic illness or nutritional deficiencies (general medicine knowledge)
• Cardiovascular involvement—XLH patients can have elevated blood pressure and left ventricular hypertrophy, so obtain baseline blood pressure measurements and consider echocardiogram if hypertension or cardiac symptoms are present 1
• Exclude dehydration, anemia, or medication effects (general medicine knowledge)

Management Algorithm

If XLH is Confirmed:

Conventional treatment in children with XLH includes:

• Oral phosphate supplements (20–60 mg/kg/day of elemental phosphorus based on phenotype severity) given 4–6 times daily to maintain stable blood levels 1
• Active vitamin D (calcitriol or alfacalcidol) must always be co-administered with phosphate to prevent secondary hyperparathyroidism 1
• Monitor serum calcium and phosphate every 2 weeks initially, then monthly; PTH monthly for first 3 months, then every 3 months 4
• Target normalization of ALP levels and radiological healing of rickets 1
• Early treatment is associated with superior outcomes including improved growth, reduced bone pain, correction of leg deformities, and improved dental health 1

Safety monitoring:

• If serum calcium rises above 9.5 mg/dL (2.37 mmol/L), stop calcitriol immediately until normocalcemia returns, then resume at 50% of previous dose 4
• If serum phosphorus exceeds 4.6 mg/dL (1.49 mmol/L), hold calcitriol temporarily, initiate or up-titrate phosphate binders, and resume once phosphorus normalizes 4

If Primary Myopathy is Identified:

Management depends on specific diagnosis:

• Immune-mediated necrotizing myopathy (IMNM) requires combination immunotherapy: oral immunosuppressant, corticosteroids, and IVIG or rituximab 6
• Vitamin D deficiency-related myopathy: supplement with cholecalciferol until 25(OH)D >20 ng/mL 4, 2
• Dystrophinopathies require genetic counseling, cardiac and pulmonary monitoring, and supportive care 2, 9

Critical Pitfalls to Avoid

• Do not assume hyperphosphatemia is accurate without verification—XLH presents with hypophosphatemia, and laboratory error or misinterpretation is possible 1
• Do not administer phosphate binders if the patient has hypophosphatemia from XLH—this would worsen the condition 1
• Do not delay genetic testing for PHEX mutations, as early diagnosis and treatment of XLH significantly improve long-term outcomes 1
• Do not pursue extensive myopathy workup if CK is only modestly elevated (<3× normal) with normal EMG and no progressive weakness—this has low diagnostic yield 3, 8
• Do not overlook vitamin D deficiency as a treatable cause of proximal myopathy and elevated CK 2
• Do not ignore cardiovascular screening in XLH patients—measure blood pressure at least yearly 1